Aaron Pfau, DO
Family Medicine · Las Cruces, NMNPI 1659683944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Lilly USA, LLC at 24.2% of the total. Among family medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$920
- AstraZeneca$895
- Novo Nordisk$413
- Boehringer Ingelheim$265
- Pfizer$242
- Merck$163
- plus $900 from 20 others
What the payments were for
- Food & beverage$3,786100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 57 | $920 |
| AstraZeneca | 52 | $895 |
| Novo Nordisk | 25 | $413 |
| Boehringer Ingelheim | 14 | $265 |
| Pfizer | 15 | $242 |
| Merck | 10 | $163 |
| Amgen | 8 | $125 |
| GSK | 6 | $116 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Abbott | 3 | $63 |
| Novartis | 3 | $55 |
| Exact Sciences | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| AbbVie | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Endogastric Solutions, Inc | 1 | $34 |
| Tactile Systems Technology Inc | 2 | $28 |
| Redhill Biopharma Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
How this compares
$3,797 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 77 | $113,706 |
| OzempicSemaglutide | 44 | $95,401 |
| TrulicityDulaglutide | 67 | $82,058 |
| FarxigaDapagliflozin Propanediol | 54 | $58,967 |
| MounjaroTirzepatide | 45 | $56,619 |
| EliquisApixaban | 59 | $53,968 |
| RybelsusSemaglutide | 19 | $37,164 |
| JanuviaSitagliptin Phosphate | 20 | $32,716 |
| XareltoRivaroxaban | 18 | $28,456 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $17,108 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $15,615 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $14,557 |
| BelsomraSuvorexant | 26 | $13,276 |
| Emgality PenGalcanezumab-Gnlm | 15 | $10,865 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $7,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $920 | $138,677112 claims |
| Novo NordiskOzempic, Rybelsus | $413 | $132,56563 claims |
| Boehringer IngelheimJardiance | $265 | $113,70677 claims |
| AstraZenecaFarxiga | $895 | $58,96754 claims |
| PfizerEliquis, Paxlovid | $242 | $55,39786 claims |
| MerckJanuvia, Belsomra | $163 | $45,99146 claims |
| Johnson & JohnsonXarelto | $21 | $28,45618 claims |
| GSKBreo Ellipta | $116 | $15,61517 claims |
| AbbVieSynthroid | $43 | $2,53167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Las Cruces
- Delliah StamppLas Cruces$21K
- Conchita PazLas Cruces$16K
- Sergio HuertaLas Cruces$11K
- Brenda CuellarLas Cruces$9K
- Imelda Toledo-NeelyLas Cruces$7K
- Mai OushyLas Cruces$3K
- Jie LuoLas Cruces$3K
- Harold McFarlingFarmington$160K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.